BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home » Blogs » BioWorld MedTech Perspectives » Is Medtronic’s cancellation of GPO contracts a prelude to a trend, or just an anomaly?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Orthopedics

Is Medtronic’s cancellation of GPO contracts a prelude to a trend, or just an anomaly?

March 21, 2011
By Holland Johnson

Late last month, Medtronic (Minneapolis) reported that it was cancelling several of its largest contracts with group purchasing organizations (GPOs) worth more than $2 billion collectively. Medtronic said the decision to cancel five contracts with Novation (Irving, Texas) and another with Premier (Charlotte, North Carolina) will save it about $60 million a year.

Wall Street reacted positively to the news and some industry watchers are wondering if other companies will follow suit and bypass GPOs to sell products directly to hospitals. GPOs – which use high volume purchasing power to secure discounts for hospitals, introduce new devices to the market, and claim to save the healthcare system up to $36 billion a year – certainly hope Medtronic's action does not signal a wider trend.

Last week, Mass Device reported that Medtronic’s CFO, Gary Ellis, told analysts at an investors’ conference, that the company is not making a strategic shift away from GPO contracts

“There’s a lot of speculation around here that a strategic change is going on,” Ellis told analysts at the Barclay’s Capital Investors Conference last week in Miami. “That is not the case.”

He added that the company plans “to maintain our relationships with GPOs that are providing a benefit.”

Chris Garland, a Medtronic spokesman, told Medical Device Daily that the company canceled five of its Novation agreements in an effort to remove costs from the healthcare system. "It is important to note that Medtronic has not, as is alleged, made a decision to eliminate all GPOs," Garland said. "Rather, in the current healthcare environment where reducing costs is in the best interest of the company, healthcare providers and patients, we are reviewing our national contracts on a contract-by-contract basis to maximize the value we can provide to our customers.”

Curtis Rooney, president of the Health Industry Group Purchasing Association (Washington) told MDD it is too early to say whether or not this will set a wider trend among device manufacturers but he certainly hopes it does not. Medtronic's decision to cancel these GPO contracts is "very problematic for hospitals, because they lose their ability to negotiate and be informed during negotiations regarding price," he said. "They no longer have the ability to benchmark what the price is from a national level . . . and local level . . . there is no way to really get a sense of what the local market is."

Pete Allen, senior VP of sourcing operations at Novation, told MDD he does not believe other device makers will follow suit and cancel their GPO contracts too.

Allen noted that Medtronic's rationale for canceling the contracts, taking costs out of the healthcare system, "doesn't hold up to any level of scrutiny. It's an assault on the contracting efficiency that hospitals rely on, the reason they join GPOs to begin with."

So how does Medtronic decide which GPOs are providing a benefit, and how is having fewer GPOs, which streamline costs for hospitals, make the healthcare system better? I suspect the assumed benefit here isn’t solely for the hospital or patients.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • Art concept for gene therapy

    Gene therapies aim for the big goal of edits in vivo

    BioWorld Science
    The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing